

## **Dr Antonio Frassoldati**

### **Curriculum vitae**

Nato a Modena il 28 febbraio 1957.

Lug. 1976 Diploma di Maturità Classica

Ott. 1982 Laurea in Medicina, Università di Modena

Dic. 1985 Diploma di Specialità in Ematologia, Università di Modena

Ott. 1989 Diploma di Specialità in Oncologia, Università di Modena

Nov. 1996 Certificazione Europea in Oncologia Medica da parte di ESMO

Sett. 1989 Dirigente Medico 1° Liv di ruolo, Divisione di Oncologia Medica, Policlinico di Modena

Ott. 1998 Stage clinico presso il Breast Service del Memorial Sloan Kettering Cancer Center di New York

Lug. 2002 Responsabile Breast Unit, Dip Oncologia ed Ematologia Policlinico di Modena

Apr. 2008 Coordinatore Percorso multidisciplinare Az. Policlinico per il trattamento delle pazienti con tumore mammario

Feb. 2011 Direttore, Unità Complessa Oncologia Clinica, Azienda Ospedaliero Universitaria S. Anna, Ferrara

1990-2010 Professore a contratto Scuola Specializzazione in Oncologia, Università di Modena e Reggio Emilia

2003-2008 Professore a contratto in Oncologia, Corso di Laurea in Dietistica, Università di Modena e Reggio Emilia

2006-2010 Professore a contratto in Oncologia, Corso di Laurea in Medicina e Chirurgia, Università di Modena e Reggio Emilia

Membro dell'American Society of Clinical Oncology, dell'European Society of Medical Oncology, della Associazione Italiana di Oncologia Medica

Attività di ricerca clinica: partecipazione a numerosi trials clinici nazionali ed internazionali svolti secondo norme di GCP.

Autore in oltre 110 pubblicazioni su riviste nazionali ed internazionali, di cui 54 su riviste peer-reviewed . (Impact factor 220.39; H-Index 15)

## Bibliografia

- 1: Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P. Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. *J Clin Oncol*. 2012 Apr 9. [Epub ahead of print] PubMed PMID: 22493419.
- 2: Giuliani J, Marzola M, Indelli M, Frassoldati A. [Oncological quality indicators and Colorectal Cancer Program: data from 2009-2010 of university hospital in Ferrara, Italy]. *Recenti Prog Med*. 2012 Feb;103(2):56-61. doi: 10.1701/1045.11386. Italian. PubMed PMID: 22430748.
- 3: Giuliani J, Marzola M, Indelli M, Aliberti C, Sartori S, Lanza G, Lelli G, Frassoldati A. Gastrointestinal Stromal Tumors and Other Malignancies: a Case Series. *J Gastrointest Cancer*. 2012 Feb 19. [Epub ahead of print] PubMed PMID: 22350927.
- 4: Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. *J Clin Oncol*. 2012 Feb 20;30(6):e76-8. Epub 2011 Dec 27. PubMed PMID: 22203769.
- 5: Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. *Clin Breast Cancer*. 2012 Feb;12(1):40-8. doi: 10.1016/j.clbc.2011.08.002. Epub 2011 Oct 19. PubMed PMID: 22014381.
- 6: Guarneri V, Pecchi A, Piacentini F, Barbieri E, Dieci MV, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. *Ann Surg Oncol*. 2011 Aug;18(8):2150-7. Epub 2011 Feb 8. PubMed PMID: 21301969.
- 7: Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A, D'Amico R, Conte P. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. *Int J Biol Markers*. 2010 Apr-Jun;25(2):104-11. PubMed PMID: 20544688.
- 8: Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhász H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. *Cancer Res*. 2010 May 1;70(9):3718-29. Epub 2010 Apr 13. PubMed PMID: 20388793.
- 9: Grisendi G, Annerén C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, Luminari S, Maur M, Frassoldati A, Palazzi G, Otsuru S, Bambi F, Paolucci P, Pierfranco C, Horwitz E, Dominici M. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. *Cytotherapy*. 2010 Jul;12(4):466-77. PubMed PMID: 20353309.

- 10: Frassoldati A, Guarneri V, Conte P. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. *Cancer Biol Ther.* 2009 Aug;8(15):1456-8. Epub 2009 Aug 5. PubMed PMID: 19617703.
- 11: Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D'Amico R, Giovannelli S, Maiorana A, Jovic G, Conte P. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. *Ann Oncol.* 2009 Jul;20(7):1193-8. Epub 2009 Feb 16. PubMed PMID: 19221152.
- 12: Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Crinó L, Agostara B, Conte P. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). *Clin Breast Cancer.* 2008 Oct;8(5):453-6. PubMed PMID: 18952561.
- 13: Gennari A, De Tursi M, Carella C, Ricevuto E, Orlandini C, Frassoldati A, Conte P, Bruzzi P, Iacobelli S. Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. *Breast Cancer Res Treat.* 2009 May;115(1):131-6. Epub 2008 Sep 13. PubMed PMID: 18791821.
- 14: Guarneri V, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte P. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). *Clin Breast Cancer.* 2008 Apr;8(2):192-4. PubMed PMID: 18621618.
- 15: Bertolini F, De Matteis E, Malavasi N, Rossi G, Venturelli C, Codeluppi M, Frassoldati A, Conte PF. Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer. *Am J Clin Oncol.* 2008 Jun;31(3):308-9. PubMed PMID: 18525313.
- 16: Frassoldati A, Guarneri V, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF. Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). *Clin Breast Cancer.* 2008 Feb;8(1):97-100. PubMed PMID: 18501066.
- 17: Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andretta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. *Breast Cancer Res Treat.* 2008 Jul;110(1):127-34. Epub 2007 Aug 9. PubMed PMID: 17687648.
- 18: Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective. *Breast J.* 2007 Jan-Feb;13(1):28-35. Review. PubMed PMID: 17214790.
- 19: Guarneri V, Frassoldati A, Giovannelli S, Borghi F, Conte P. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. *Cancer Lett.* 2007 Apr 18;248(2):175-85. Epub 2006 Aug 21. Review. PubMed PMID: 16919869.
- 20: Marotta G, Frassoldati A, Zinzani P, Annino L, Brugiattelli M, Ambrosetti A, Lenoci M, Federico M, Foa R, Lauria F; Italian Cooperative group for HCL (ICGHCL). Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. *Eur J Haematol.* 2006 Aug;77(2):109-13. PubMed PMID: 16856905.

- 21: Maur M, Guarneri V, Frassoldati A, Conte PF. Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. *Ann Oncol*. 2006 May;17 Suppl 5:v158-64. Review. PubMed PMID: 16807447.
- 22: Frassoldati A, Maur M, Guarneri V, Nicolini M, Conte PF. Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. *Clin Breast Cancer*. 2005 Oct;6(4):315-24. Review. PubMed PMID: 16277881.
- 23: Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clinical Research. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. *Clin Breast Cancer*. 2005 Aug;6(3):253-9. PubMed PMID: 16137437.
- 24: Carlini P, Ferretti G, Di Cosimo S, Colella E, Tonachella R, Romiti A, Tomao S, Frassoldati A, Papaldo P, Fabi A, Ruggeri EM, Cognetti F. Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? *J Steroid Biochem Mol Biol*. 2003 Jul;86(1):107-9. PubMed PMID: 12943750.
- 25: Roila F, Ballatori E, Patoia L, Palazzo S, Veronesi A, Frassoldati A, Cetto G, Cinieri S, Goldhirsch A; Drug Utilization Review Team in Oncology. Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. *Ann Oncol*. 2003 Jun;14(6):843-8. PubMed PMID: 12796020.
- 26: Morabito F, Baldini L, Stelitano C, Luminari S, Frassoldati A, Merli F, Colombi M, Sabbatini R, Brugiattelli M, Federico M; Gruppo Italiano per lo studio dei linfomi. Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy. *Leuk Lymphoma*. 2002 Oct;43(10):1933-8. PubMed PMID: 12481887.
- 27: Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A, Passalacqua R, Bian AR, Rodinò C, Rondini E, Algeri R, Di Sarra S, De Angelis V, Cocconi G, Tonato M. Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. *Eur J Cancer*. 2002 Nov;38(17):2279-88. PubMed PMID: 12441265.
- 28: Carlini P, Frassoldati A, De Marco S, Casali A, Ruggeri EM, Nardi M, Papaldo P, Fabi A, Paoloni F, Cognetti F. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? *Ann Oncol*. 2001 Nov;12(11):1539-43. PubMed PMID: 11822752.
- 29: Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A, Annino L, Chisesi T, Pagnucco G, Invernizzi R, Spriano M, Resegotti L, Bendandi M, Damasio EE; Italian Cooperative Group for the Study of Hairy Cell Leukemia. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. *J Clin Oncol*. 2002 Feb 1;20(3):638-46. PubMed PMID: 11821443.
- 30: Cantore M, Pederzoli P, Cornalba G, Fiorentini G, Guadagni S, Misericocchi L, Frassoldati A, Ceravolo C, Smerieri F, Muchmore JH. Intra-arterial chemotherapy for unresectable pancreatic cancer. *Ann Oncol*. 2000 May;11(5):569-73. PubMed PMID: 10907950.

- 31: Cocconi G, Bisagni G, Bella M, Acito L, Anastasi P, Carpi A, Di Costanzo F, Frassoldati A, Mosconi A, Borrini A, Buzzi P. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. *Am J Clin Oncol*. 1999 Dec;22(6):593-600. PubMed PMID: 10597744.
- 32: Longo G, Fiorani C, Sacchi S, Callea V, Lombardo M, Federico M, Stelitano C, Angrilli F, Vallisa D, Gobbi PG, Ilariucci F, Frassoldati A, Petrini M, Silingardi V. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL). *Haematologica*. 1999 May;84(5):425-30. PubMed PMID: 10329921.
- 33: Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V. Changes of biological features in breast cancer cells determined by primary chemotherapy. *Breast Cancer Res Treat*. 1997 Jul;44(3):185-92. PubMed PMID: 9266097.
- 34: Luppi M, Morselli M, Bandieri E, Federico M, Marasca R, Barozzi P, Ferrari MG, Savarino M, Frassoldati A, Torelli G. Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. *Ann Oncol*. 1996 Aug;7(6):619-24. PubMed PMID: 8879377
- 35: Gobbi PG, Pieresca C, Frassoldati A, Carotenuto M, Di Renzo N, La Sala A, Berté R, Avanzini P, Federico M, Silingardi V, Ascari E. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience. *J Clin Oncol*. 1996 Feb;14(2):527-33. PubMed PMID: 8636767.
- 36: Silingardi V, Federico M, Cavanna L, Avanzini P, Gobbi PG, Lombardo M, Carotenuto M, Frassoldati A, Pieresca C, Vallisa D, et al. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). *Leuk Lymphoma*. 1995 Apr;17(3-4):313-20. PubMed PMID: 8580801.
- 37: Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiattelli M, Annino L, Baldini L, Capnist G, Chisesi T, di Celle PF, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. *Ann Oncol*. 1994 Oct;5(8):725-31. PubMed PMID: 7826905.
- 38: Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, Dini E, Resegotti L, Damasio EE, Silingardi V. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. *Leuk Lymphoma*. 1994 Apr;13(3-4):307-16. Review. PubMed PMID: 7519510.
- 39: Damasio EE, Frassoldati A. Splenectomy following complete response to alpha interferon (IFN) therapy in patients with hairy cell leukemia (HCL): results of the HCL88 protocol. Italian Cooperative Group for the Study of Hairy Cell Leukemia (ICGHCL). *Leuk Lymphoma*. 1994;14 Suppl 1:95-8. PubMed PMID: 7820061.
- 40: Federico M, Frassoldati A, Lamparelli T, Dini E, Resegotti L, Damasio EE. Hairy cell leukemia: the Italian Cooperative Group experience. *Leukemia*. 1992 Nov;6 Suppl 4:147-8. PubMed PMID: 1279328.

- 41: Casolo P, Frassoldati A, Giacò M, Lazzaretti MG, Mosca D, Piccinini L. [A case of primary non-Hodgkin's lymphoma of the adrenal gland]. *Minerva Med.* 1991 Nov;82(11):781-5. Review. Italian. PubMed PMID: 1766582.
- 42: Capnist G, Federico M, Chisesi T, Resegotti L, Pagnucco G, Castoldi GL, Lamparelli T, Frassoldati A, Guarnaccia C, Leoni P, et al. Should alpha interferon be used as primary treatment for hairy cell leukemia? Italian Cooperative Group for Hairy Cell Leukemia. *Leuk Res.* 1991;15(6):419-26. PubMed PMID: 1861528.
- 43: Frassoldati A, Federico M, Barbieri F, Brausi M, Pollastri C, Berri G, Castagnetti G, Palladini PP, Silingardi V. Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer. *Med Oncol Tumor Pharmacother.* 1991;8(2):99-103. PubMed PMID: 1749307.
- 44: Damasio EE, Federico M, Frassoldati A, Lamparelli T, Annino L, Bernasconi C, Chisesi T, Foà R, Lauria F, Pagnucco G, et al. Splenectomy after initial therapy with alpha-IFN in patients with hairy-cell leukemia (HCL): a multi-center study by the Italian Cooperative Group for HCL. Preliminary results. *Eur J Haematol Suppl.* 1990;52:29-31. PubMed PMID: 2279542.
- 45: Federico M, Chisesi T, Lauria F, Bernasconi C, Capnist G, Castoldi G, Damasio E, Pagnucco G, Frassoldati A, Resegotti L, et al. Human lymphoblastoid interferon as initial therapy in hairy cell leukaemia: a multicentre study in non-splenectomized patients. Italian Cooperative Group for Hairy Cell Leukemia. *Br J Haematol.* 1989 May;72(1):54-6. PubMed PMID: 2660901.
- 46: Frassoldati A, Barbieri F, Piccinini L, Federico M, Silingardi V. [Current role of chemotherapy in musculo-invasive transitional carcinoma of the bladder]. *Minerva Urol Nefrol.* 1989 Apr-Jun;41(2):103-8. Review. Italian. PubMed PMID: 2672379.
- 47: Silingardi V, Davolio-Marani S, Federico M, Piccinini L, Frassoldati A, Sarti M, Burani A, Canossi G. Bone marrow infiltration in hairy cell leukemia after interferon therapy detected by magnetic resonance imaging. *Eur J Cancer Clin Oncol.* 1989 Feb;25(2):209-13. PubMed PMID: 2702977.
- 48: Federico M, Frassoldati A, Pagnucco G, Lamparelli T, Capnist G, Chisesi T, Guarnaccia C, Lauria F, Resegotti L, Rossi G, et al. Human lymphoblastoid alpha-interferon for hairy cell leukemia. An update of the Italian Cooperative Group. *Bone Marrow Transplant.* 1989 Jan;4 Suppl 1:179-81. PubMed PMID: 2653499.
- 49: Silingardi V, Federico M, Frassoldati A, Barbieri F, Palomba G, Mauri C. Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases treated with a MOPP-modified protocol. *Acta Haematol.* 1989;82(4):179-86. PubMed PMID: 2511719.
- 50: Curci G, Frassoldati A, Zioni F, Lasagni D, Malaguti R, Zaniol P, Piccinini L. Urinary albumin excretion during a moderate physical exercise in healthy subjects. *Panminerva Med.* 1988 Jan-Mar;30(1):42-4. PubMed PMID: 3419852.
- 51: Frassoldati A, Lasagni D, Carafa D, Curci G. [Scintigraphy with indium-111-oxine in the diagnosis of occult inflammation foci. Personal contribution]. *Minerva Med.* 1988 Jan;79(1):61-4. Italian. PubMed PMID: 3124022.

52: Curci G, Frassoldati A, Zioni F, Zaniol P, Piccinini L. Plasma fibronectin in hemoblastosis. *Int J Biol Markers*. 1987 May-Aug;2(2):71-4. PubMed PMID: 3451931

53: Curci G, Zioni F, Frassoldati A. [Therapy of idiopathic thrombocytopenic purpura]. *Clin Ter*. 1987 Jan 15;120(1):45-50. Review. Italian. PubMed PMID: 2461827.

54: Zioni F, Pompei G, Frassoldati A, Messerotti A. [Idiopathic pachydermoperiostitis. Description of a case]. *Minerva Med*. 1985 Mar 24;76(12):575-8. Italian. PubMed PMID: 3991029.